Hanmi’s Licensing Success Driven By Strong Clinical Strategy
This article was originally published in PharmAsia News
Executive Summary
Hanmi Pharm's recent record license agreements with multinational pharma giants clearly show that the company may be a step or two ahead of its South Korean rivals in R&D and also indicate its strength in oncology. A local brokerage notes its clinical development strategy may also have played a role in this success and suggests ways other domestic pharmas can reduce failures.